Diabetes & Metabolic Syndrome, 13, 440443
While many people associate vitamin C strictly with immune support during the winter months, its role is much broader
Clinical and translational studies have reported substantial changes in body weight and adipose tissue mass when the compound is evaluated in controlled trials and metabolic models, suggesting that multi-receptor agonism can alter energy balance through integrated endocrine signaling mechanisms [2][3][5]
This landmark study led to FDA approval expansion in March 2024 for Wegovy (semaglutide 2.4 mg) to reduce the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with cardiovascular disease and either obesity or overweight
The FDA approved semaglutide (Wegovy) in 2021 for chronic weight management in adults with a BMI of 27 or higher and at least one weight-related health condition, or a BMI of 30 or higher regardless of comorbidities
Top GLP-1 Nutritional Support Market Dynamics The GLP-1 nutritional support market is experiencing significant expansion, fueled by the growing adoption of GLP-1 medications for weight management and metabolic health
